Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-474 | HER2amp | Luminal | ZM-447439 | AURK | AURK | 12056.16 | uM | 18.20560 | 49.54740 | -0.4446 | -1.0000 | 1.0973 | 0.3126 | 0.7841 | 0.9124 | |
HCC1395 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 7814.016 | uM | 8.07790 | 51.84210 | 0.1222 | -1.0000 | 0.5910 | 0.1669 | 0.9925 | 0.8623 | |
MDA-MB-175-VII | HR+ | Luminal | Sigma A6730 | AKT | AKT | 10818.153 | uM | 1.31410 | 4.28860 | -0.9481 | -1.0000 | 0.9288 | 0.5228 | 0.9568 | 0.6469 | |
BT-483 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 7801.016 | uM | 22.32320 | 38.86550 | -0.9618 | -1.0000 | 1.9813 | 0.3751 | 0.8751 | 0.4118 | ||
BT-483 | HR+ | Luminal | 17-AAG | HSP90 | HSP90 | 9186.037 | uM | 0.14337 | 1.08130 | -0.9871 | -1.0000 | 0.5437 | 0.6949 | 0.9553 | 0.5199 | |
HMT-3522 S1 | Unknown | Unknown | GSK923295 | CENPE | Kinesin | 7911.001 | uM | 0.48448 | 1.82110 | -0.9500 | -1.0000 | 0.8297 | 0.5219 | 0.9328 | 1.2005 | |
BT-483 | HR+ | Luminal | 5-DFUR | TYMS | TYMS | 11855.143 | uM | 22.20910 | 916.2230 | -0.3934 | -1.0000 | 0.2954 | 0.5025 | 0.9381 | 0.5372 | |
MDA-MB-361 | HER2amp | Luminal | CGC-11047 | Polyamine analogue | 7895.018 | uM | 202.80460 | 1000.00000 | -0.8635 | -1.0000 | 0.6886 | 0.3918 | 0.7644 | 1.2916 | ||
SUM225CWN | HER2amp | Basal A | NSC 663284 | CDC25 | CDC | 12098.159 | uM | 2.24320 | 4.11360 | -0.9847 | -1.0000 | 1.8117 | 0.5831 | 0.9949 | 1.0261 | |
HCC70 | TNBC | Basal A | Nutlin 3a | MDM2 | MDM2 | 7470.066 | uM | 16.9690 | 35.8280 | -0.4446 | -1.0000 | 1.4700 | 0.2042 | 0.9482 | 1.0766 | |
BT-483 | HR+ | Luminal | 5-DFUR | TYMS | TYMS | 10696.143 | uM | 63.52740 | 851.88480 | -0.3979 | -1.0000 | 0.4232 | 0.4208 | 0.9738 | 0.5188 | |
SUM225CWN | HER2amp | Basal A | Nutlin 3a | MDM2 | MDM2 | 7533.066 | uM | 15.83360 | 22.27750 | -0.9482 | -1.0000 | 3.2175 | 0.1961 | 0.9891 | 0.8676 | |
SUM225CWN | HER2amp | Basal A | Nutlin 3a | MDM2 | MDM2 | 7534.066 | uM | 20.6350 | 33.12770 | -0.6725 | -1.0000 | 2.3208 | 0.1603 | 0.9915 | 1.0191 | |
HCC1395 | TNBC | Basal B | Glycyl-H-1152 | ROCK2 | 12000.169 | uM | 5.15510 | 75.12560 | -0.0066 | -1.0000 | 0.4101 | 0.2688 | 0.9786 | 0.8565 | ||
184B5 | NM | Basal | Nutlin 3a | MDM2 | MDM2 | 5896.066 | uM | 2.29050 | 11.45910 | -0.9381 | -1.0000 | 0.6824 | 0.3705 | 0.8514 | 1.4224 | |
SUM225CWN | HER2amp | Basal A | Oxamflatin | HDAC | HDAC | 12098.147 | uM | 0.85121 | 2.73110 | -0.9191 | -1.0000 | 0.9424 | 0.5630 | 0.9647 | 1.1904 | |
MDA-MB-134-VI | HR+ | Luminal | Glycyl-H-1152 | ROCK2 | 12206.16 | uM | 1.22030 | 5.55730 | -0.8227 | -1.0000 | 0.7247 | 0.4363 | 0.9848 | 0.9874 | ||
HCC1395 | TNBC | Basal B | GSK1070916 | AURK | AURK | 9258.001 | uM | 0.09421 | 1.1910 | -0.9841 | -1.0000 | 0.4330 | 0.6113 | 0.8765 | 0.7137 | |
SUM225CWN | HER2amp | Basal A | PD173074 | FGFR1/3 | RTK | 10579.1 | uM | 13.56940 | 23.08410 | -0.8067 | -1.0000 | 2.0677 | 0.2038 | 0.9791 | 0.9677 | |
BT-483 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 11855.158 | uM | 0.79652 | 3.89470 | -0.9969 | -1.0000 | 0.6922 | 0.6114 | 0.8444 | 0.6941 | |
LY2 | HR+ | Luminal | Valproic acid | HDAC | HDAC | 10816.143 | uM | 391.61530 | 999.99910 | -0.9998 | -1.0000 | 1.1719 | 0.4856 | 0.8408 | 0.4975 | |
HCC1395 | TNBC | Basal B | GSK1070916 | AURK | AURK | 7816.001 | uM | 0.59860 | 2.77790 | -0.9806 | -1.0000 | 0.7158 | 0.4383 | 0.9545 | 1.0243 | |
HCC1395 | TNBC | Basal B | GSK1070916 | AURK | AURK | 7813.001 | uM | 5.56960 | 8.06020 | -0.9735 | -1.0000 | 2.9723 | 0.1992 | 0.9944 | 0.7338 |